Bayabao, Alaizah D.
HRN: 21-95-47 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/15/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
10/15/2022
10/21/2022
IV
130mg
Q8
Septic Shock Secondary To AGE
Waiting Final Action
Indication: Empiric Type of Infection: Intra-abdominal Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes